Novel Mechanisms for Resolution of Liver Inflammation: Therapeutic Implications

Abstract

Traditional concepts have classically viewed resolution of inflammation as a passive process yet insight into the pathways by which inflammation is resolved has challenged this idea. Resolution has been revealed as a highly dynamic and active event that is essential to counteract the dysregulated inflammatory response that drives diverse disease states. Abrogation of the hepatic inflammatory response through the stimulation of proresolving mechanisms represents a new paradigm in the setting of chronic inflammatory-driven liver diseases. Elucidation of the role of different cells of the innate and adaptive immune system has highlighted the interplay between them as an important orchestrator of liver repair. A finely tuned interaction between neutrophils and macrophages has risen as revolutionary mechanism that drives the restoration of hepatic function and architecture. Specialized proresolving mediators have also been shown to act as stop signals of the inflammatory response and promote resolution as well as tissue regeneration. In this review, we discuss the discovery and understanding of the mechanisms by which inflammation is resolved and highlight novel proresolving pathways that represent promising therapeutic strategies.

Keywords

liver inflammation - resolution - immune system - macrophage - neutrophil - lipid mediators - novel therapy

^* These authors contributed equally.

Publication History

Article published online:
24 March 2021

• References

• 1 Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol 2019; 70 (01) 151-171
• 2 GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020; 5 (03) 245-266
• 3 Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. BMJ 2018; 362: k2817
• 4 Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol 2018; 15 (06) 349-364
• 5 Marcellin P, Kutala BK. Liver diseases: a major, neglected global public health problem requiring urgent actions and large-scale screening. Liver Int 2018; 38 (Suppl. 01) 2-6
• 6 Sun B, Karin M. Obesity, inflammation, and liver cancer. J Hepatol 2012; 56 (03) 704-713
• 7 Robinson MW, Harmon C, O'Farrelly C. Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol 2016; 13 (03) 267-276
• 8 Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454 (7203): 428-435
• 9 Ramachandran P, Iredale JP, Fallowfield JA. Resolution of liver fibrosis: basic mechanisms and clinical relevance. Semin Liver Dis 2015; 35 (02) 119-131
• 10 Fullerton JN, Gilroy DW. Resolution of inflammation: a new therapeutic frontier. Nat Rev Drug Discov 2016; 15 (08) 551-567
• 11 Yang W, Tao Y, Wu Y. et al. Neutrophils promote the development of reparative macrophages mediated by ROS to orchestrate liver repair. Nat Commun 2019; 10 (01) 1076
• 12 Musso G, Gambino R, Cassader M, Paschetta E, Sircana A. Specialized proresolving mediators: enhancing nonalcoholic steatohepatitis and fibrosis resolution. Trends Pharmacol Sci 2018; 39 (04) 387-401
• 13 Newson J, Stables M, Karra E. et al. Resolution of acute inflammation bridges the gap between innate and adaptive immunity. Blood 2014; 124 (11) 1748-1764
• 14 Heymann F, Tacke F. Immunology in the liver—from homeostasis to disease. Nat Rev Gastroenterol Hepatol 2016; 13 (02) 88-110
• 15 Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology 2012; 143 (05) 1158-1172
• 16 Kubes P, Jenne C. Immune responses in the liver. Annu Rev Immunol 2018; 36: 247-277
• 17 Seitz HK, Bataller R, Cortez-Pinto H. et al. Alcoholic liver disease. Nat Rev Dis Primers 2018; 4 (01) 16
• 18 Ibrahim SH, Hirsova P, Gores GJ. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation. Gut 2018; 67 (05) 963-972
• 19 Wree A, McGeough MD, Inzaugarat ME. et al. NLRP3 inflammasome driven liver injury and fibrosis: roles of IL-17 and TNF in mice. Hepatology 2018; 67 (02) 736-749
• 20 Kohli P, Levy BD. Resolvins and protectins: mediating solutions to inflammation. Br J Pharmacol 2009; 158 (04) 960-971
• 21 Buckley CD, Gilroy DW, Serhan CN, Stockinger B, Tak PP. The resolution of inflammation. Nat Rev Immunol 2013; 13 (01) 59-66
• 22 Calvente CJ, Tameda M, Johnson CD. et al. Neutrophils contribute to spontaneous resolution of liver inflammation and fibrosis via microRNA-223. J Clin Invest 2019; 129 (10) 4091-4109
• 23 Liew PX, Lee WY, Kubes P. iNKT cells orchestrate a switch from inflammation to resolution of sterile liver injury. Immunity 2017; 47 (04) 752-765.e5
• 24 Ramachandran P, Pellicoro A, Vernon MA. et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci U S A 2012; 109 (46) E3186-E3195
• 25 Rantakari P, Patten DA, Valtonen J. et al. Stabilin-1 expression defines a subset of macrophages that mediate tissue homeostasis and prevent fibrosis in chronic liver injury. Proc Natl Acad Sci U S A 2016; 113 (33) 9298-9303
• 26 Triantafyllou E, Pop OT, Possamai LA. et al. MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure. Gut 2018; 67 (02) 333-347
• 27 Campana L, Starkey Lewis PJ, Pellicoro A. et al. The STAT3-IL-10-IL-6 pathway is a novel regulator of macrophage efferocytosis and phenotypic conversion in sterile liver injury. J Immunol 2018; 200 (03) 1169-1187
• 28 Starkey Lewis P, Campana L, Aleksieva N. et al. Alternatively activated macrophages promote resolution of necrosis following acute liver injury. J Hepatol 2020; 73 (02) 349-360
• 29 Heymann F, Peusquens J, Ludwig-Portugall I. et al. Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology 2015; 62 (01) 279-291
• 30 Elsegood CL, Chan CW, Degli-Esposti MA. et al. Kupffer cell-monocyte communication is essential for initiating murine liver progenitor cell-mediated liver regeneration. Hepatology 2015; 62 (04) 1272-1284
• 31 Guillot A, Tacke F. Liver macrophages: old dogmas and new insights. Hepatol Commun 2019; 3 (06) 730-743
• 32 Graubardt N, Vugman M, Mouhadeb O. et al. Ly6C^hi monocytes and their macrophage descendants regulate neutrophil function and clearance in acetaminophen-induced liver injury. Front Immunol 2017; 8: 626
• 33 Wan J, Benkdane M, Teixeira-Clerc F. et al. M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology 2014; 59 (01) 130-142
• 34 Abshagen K, Eipel C, Kalff JC, Menger MD, Vollmar B. Loss of NF-kappaB activation in Kupffer cell-depleted mice impairs liver regeneration after partial hepatectomy. Am J Physiol Gastrointest Liver Physiol 2007; 292 (06) G1570-G1577
• 35 Soehnlein O, Steffens S, Hidalgo A, Weber C. Neutrophils as protagonists and targets in chronic inflammation. Nat Rev Immunol 2017; 17 (04) 248-261
• 36 Signaling by Reactive Oxygen Species. Signaling by reactive oxygen species. Mol Aspects Med 2018; 63: 1-2
• 37 Van Herck MA, Weyler J, Kwanten WJ. et al. The differential roles of t cells in non-alcoholic fatty liver disease and obesity. Front Immunol 2019; 10: 82
• 38 Zhang C, Li L, Feng K, Fan D, Xue W, Lu J. 'Repair' treg cells in tissue injury. Cell Physiol Biochem 2017; 43 (06) 2155-2169
• 39 Claassen MA, de Knegt RJ, Tilanus HW, Janssen HL, Boonstra A. Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis. J Hepatol 2010; 52 (03) 315-321
• 40 Popovic B, Golemac M, Podlech J. et al. IL-33/ST2 pathway drives regulatory T cell dependent suppression of liver damage upon cytomegalovirus infection. PLoS Pathog 2017; 13 (04) e1006345
• 41 Gao Y, Liu Y, Yang M. et al. IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis. Oncotarget 2016; 7 (23) 33649-33661
• 42 Katz SC, Ryan K, Ahmed N. et al. Obstructive jaundice expands intrahepatic regulatory T cells, which impair liver T lymphocyte function but modulate liver cholestasis and fibrosis. J Immunol 2011; 187 (03) 1150-1156
• 43 Wintermeyer P, Cheng CW, Gehring S. et al. Invariant natural killer T cells suppress the neutrophil inflammatory response in a mouse model of cholestatic liver damage. Gastroenterology 2009; 136 (03) 1048-1059
• 44 Körner A, Zhou E, Müller C. et al. Inhibition of Δ24-dehydrocholesterol reductase activates pro-resolving lipid mediator biosynthesis and inflammation resolution. Proc Natl Acad Sci U S A 2019; 116 (41) 20623-20634
• 45 Kang JW, Lee SM. Resolvin D1 protects the liver from ischemia/reperfusion injury by enhancing M2 macrophage polarization and efferocytosis. Biochim Biophys Acta 2016; 1861 (9 Pt A): 1025-1035
• 46 Neuhofer A, Zeyda M, Mascher D. et al. Impaired local production of proresolving lipid mediators in obesity and 17-HDHA as a potential treatment for obesity-associated inflammation. Diabetes 2013; 62 (06) 1945-1956
• 47 Thomas JA, Pope C, Wojtacha D. et al. Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function. Hepatology 2011; 53 (06) 2003-2015
• 48 Ma PF, Gao CC, Yi J. et al. Cytotherapy with M1-polarized macrophages ameliorates liver fibrosis by modulating immune microenvironment in mice. J Hepatol 2017; 67 (04) 770-779
• 49 Mitchell C, Couton D, Couty JP. et al. Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice. Am J Pathol 2009; 174 (05) 1766-1775
• 50 Krenkel O, Puengel T, Govaere O. et al. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology 2018; 67 (04) 1270-1283
• 51 Gong W, Zhu H, Lu L, Hou Y, Dou H. A benzenediamine analog FC-99 drives M2 macrophage polarization and alleviates lipopolysaccharide- (LPS-) induced liver injury. Mediators Inflamm 2019; 2019: 7823069
• 52 Gilroy DW, Lawrence T, Perretti M, Rossi AG. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov 2004; 3 (05) 401-416
• 53 Ma HM, Wu Z, Nakanishi H. Phosphatidylserine-containing liposomes suppress inflammatory bone loss by ameliorating the cytokine imbalance provoked by infiltrated macrophages. Lab Invest 2011; 91 (06) 921-931
• 54 Maradana MR, Yekollu SK, Zeng B. et al. Immunomodulatory liposomes targeting liver macrophages arrest progression of nonalcoholic steatohepatitis. Metabolism 2018; 78: 80-94
• 55 Patten DA, Shetty S. The role of stabilin-1 in lymphocyte trafficking and macrophage scavenging in the liver microenvironment. Biomolecules 2019; 9 (07) 283
• 56 Oo YH, Sakaguchi S. Regulatory T-cell directed therapies in liver diseases. J Hepatol 2013; 59 (05) 1127-1134
• 57 Ma X, Hua J, Mohamood AR, Hamad AR, Ravi R, Li Z. A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury. Hepatology 2007; 46 (05) 1519-1529
• 58 Longhi MS, Hussain MJ, Kwok WW, Mieli-Vergani G, Ma Y, Vergani D. Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis. Hepatology 2011; 53 (02) 536-547
• 59 Curbishley SM, Eksteen B, Gladue RP, Lalor P, Adams DH. CXCR 3 activation promotes lymphocyte transendothelial migration across human hepatic endothelium under fluid flow. Am J Pathol 2005; 167 (03) 887-899
• 60 Jeffery HC, Jeffery LE, Lutz P. et al. Low-dose interleukin-2 promotes STAT-5 phosphorylation, T_reg survival and CTLA-4-dependent function in autoimmune liver diseases. Clin Exp Immunol 2017; 188 (03) 394-411
• 61 Lynch L, Nowak M, Varghese B. et al. Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity 2012; 37 (03) 574-587
• 62 Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 2008; 49 (05) 821-830
• 63 Chen D, Gao X, Wang J. et al. Activation of hepatic iNKT2 cells by α-GalCer ameliorates hepatic steatosis induced by high-fat diet in C57BL/6J mice. Int Immunopharmacol 2019; 74: 105727
• 64 Xiang X, Feng D, Hwang S. et al. Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice. J Hepatol 2020; 72 (04) 736-745
• 65 González-Périz A, Horrillo R, Ferré N. et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J 2009; 23 (06) 1946-1957
• 66 Martínez-Fernández L, González-Muniesa P, Laiglesia LM. et al. Maresin 1 improves insulin sensitivity and attenuates adipose tissue inflammation in ob/ob and diet-induced obese mice. FASEB J 2017; 31 (05) 2135-2145
• 67 Rius B, Duran-Güell M, Flores-Costa R. et al. The specialized proresolving lipid mediator maresin 1 protects hepatocytes from lipotoxic and hypoxia-induced endoplasmic reticulum stress. FASEB J 2017; 31 (12) 5384-5398
• 68 Börgeson E, Johnson AM, Lee YS. et al. Lipoxin A4 attenuates obesity-induced adipose inflammation and associated liver and kidney disease. Cell Metab 2015; 22 (01) 125-137
• 69 Rius B, Titos E, Morán-Salvador E. et al. Resolvin D1 primes the resolution process initiated by calorie restriction in obesity-induced steatohepatitis. FASEB J 2014; 28 (02) 836-848
• 70 Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: a review. World J Gastroenterol 2017; 23 (36) 6549-6570